Tiziana Life Sciences (TLSA) Stock Price, News & Analysis

Company Overview

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors. In parallel, Tiziana’s wholly owned biologic portfolio includes foralumab, a fully human anti‐CD3 monoclonal antibody investigated for autoimmune and neuroinflammatory conditions, and TZLS‐501, an anti‐interleukin‐6 receptor antibody initially evaluated for acute respiratory distress syndrome associated with infectious diseases.

Tiziana Life Sciences serves markets in North America and Europe, collaborating with academic centers and contract research organizations to conduct its clinical programs. The company’s multidisciplinary team combines expertise in translational research, medicinal chemistry and antibody engineering to support its pipeline from early discovery through clinical development.

Since joining Tiziana as chief executive officer in 2019, Dr. Bahija Jallal has leveraged her experience in biotechnology and immunotherapy to steer the company’s strategic direction. Supported by a board of directors and scientific advisory board with extensive pharmaceutical development backgrounds, Tiziana is advancing its programs toward regulatory milestones with the goal of addressing unmet needs in cancer and immune‐mediated diseases.

Key Stats

• Today's Range: $1.41 to $1.63
• 50-Day Range: $1.15 to $1.61
• 52-Week Range: $1.14 to $2.60
• Volume: 575,559 shs
• Average Volume: 210,940 shs
• Market Capitalization: $188.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Tiziana Life Sciences Stock Analysis - MarketRank™

Tiziana Life Sciences scored higher than 19% of companies evaluated by MarketBeat, and ranked 794th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Tiziana Life Sciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Tiziana Life Sciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

1.78% of the float of Tiziana Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Tiziana Life Sciences has a short interest ratio ("days to cover") of 8.54.

Change versus previous month

Short interest in Tiziana Life Sciences has recently increased by 5.68%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tiziana Life Sciences does not currently pay a dividend.

Dividend Growth

Tiziana Life Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.69

News Sentiment

Tiziana Life Sciences has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Tiziana Life Sciences this week, compared to 2 articles on an average week.

Search Interest

8 people have searched for TLSA on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tiziana Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

39.82% of the stock of Tiziana Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Tiziana Life Sciences has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/01/2026
• Today: 5/25/2026
• Next Earnings (Estimated): 6/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TLSA
• CIK: 1723069
• Web: www.tizianalifesciences.com
• Phone: 44-20-7495-2379
• Fax: N/A
• Employees: 8
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.76
• Quick Ratio: 0.76

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 127,260,000
• Free Float: 76,584,000
• Market Cap: $188.34 million
• Optionable: Optionable
• Beta: 0.42